Anemia is a common complication of chronic kidney disease (CKD), with prevalence increasing as kidney function declines and affecting up to 60% of patients with non-dialysis-dependent CKD.^[1] It is associated with impaired quality of life, poorer renal outcomes, and increased morbidity and mortality. Management includes individualized erythropoiesis-stimulating agents (ESAs), oral or intravenous iron, and transfusion when necessary.^[2] Iron supplementation can improve hemoglobin and ferritin levels while reducing ESA and transfusion requirements. Emerging hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) offer a potential therapeutic alternative, although further evidence is needed to establish their long-term clinical benefits and safety.